Observing lung nodules using a mobile app
Mobile Lung Nodule Observatory for Worldwide, Evidenced - Based Research
Chinese Alliance Against Lung Cancer · NCT02693496
This study is testing a smartphone app to help track and manage lung nodules in patients over 10 years to see if watching them closely or removing them is the best way to handle them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Chinese Alliance Against Lung Cancer (other) |
| Drugs / interventions | chemotherapy |
| Locations | 34 sites (Beijing and 33 other locations) |
| Trial ID | NCT02693496 on ClinicalTrials.gov |
What this trial studies
This observational study aims to understand the symptoms and management of solitary pulmonary nodules through a smartphone application. Patients with lung nodules less than 3cm will be monitored over a 10-year period using a three-step testing method that includes medical history collection, non-invasive, and invasive examinations. The study seeks to establish a clear standard of care for managing these nodules, comparing surgical removal and observation as potential solutions. This innovative approach leverages technology to gather evidence-based data on the evolution of lung nodules.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 90 with a chest lesion less than 3cm and access to a smartphone.
Not a fit: Patients who do not own a smartphone or have previously undergone treatment for lung cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for patients with lung nodules, enhancing their quality of life.
How similar studies have performed: This approach is novel and has not been tested in prior studies, either in China or internationally.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 18 and 90 * There is a chest lesion less than 3cm width (examined by Thin-Section CT) * The patient or his family member owns a smartphone * Signed informed consent * Completed the installation and registration of mobile terminal software online * Willing to complete a 10-year period of follow-up Exclusion Criteria: * Not equipped with a smartphone * Cannot complete the installation or registration of smartphone application software online * Received prior chemotherapy medications for lung cancer or received lung surgical removal treatment
Where this trial is running
Beijing and 33 other locations
- Beijing Union Hospital — Beijing, China (RECRUITING)
- General Hospital of PLA — Beijing, China (RECRUITING)
- Hebei Pronvince Cangzhou City People's Hospital — Cangzhou, China (RECRUITING)
- Xiaya Hospital Central South Unversity — Changsha, China (RECRUITING)
- Anhui Province Chaoyang Hospital — Chaoyang, China (RECRUITING)
- West China Hospital Sichuan University — Chengdu, China (RECRUITING)
- No.1 Hospital Chongqing Medical University — Chongqing, China (RECRUITING)
- Western East Hospital No. 3 PLA Medical University — Chongqing, China (RECRUITING)
- No. 2 Hospital Dalian Medical University — Dalian, China (RECRUITING)
- Guizhou Province People's Hospital — Guizhou, China (RECRUITING)
- International Hospital Zhejiang University — Hangzhou, China (RECRUITING)
- No. 1 Hospital Zhejiang University Medical College — Hangzhou, China (RECRUITING)
- Yunnan Province Cancer Hospital — Kunming, China (RECRUITING)
- Shandong Province Liaocheng City People's Hospital — Liaocheng, China (RECRUITING)
- No. 2 Hospital Fujian Medical University — Quanzhou, China (RECRUITING)
- Kecheng District Hospital — Quzhou, China (RECRUITING)
- Shanghai Zhongshan Hospital — Shanghai, China (RECRUITING)
- Minhang District Hospital Fudan University — Shanghai, China (RECRUITING)
- Putuo District Central Hospital Shanghai Chinese Medical University — Shanghai, China (RECRUITING)
- Ruici Clinic — Shanghai, China (RECRUITING)
- No. 2 Hospital Tianjin Chinese Medical University — Tianjin, China (RECRUITING)
- Weifang City No.2 People's Hospital — Weifang, China (RECRUITING)
- Wudang Hospital Guiyang Medical College — Wudang, China (RECRUITING)
- Wuhu City No. 2 Hopsital — Wuhu, China (RECRUITING)
- No. 5 Wuxi People's Hospital — Wuxi, China (RECRUITING)
- Xiamen City No.3 People's Hospital — Xiamen, China (RECRUITING)
- Xining Hospital No.4 PLA University — Xian, China (RECRUITING)
- Yantai City Taishan Hopsital — Yantai, China (RECRUITING)
- Henan Province People's Hospital — Zhengzhou, China (RECRUITING)
- No. 1 Hospital Zhengzhou University — Zhengzhou, China (RECRUITING)
- Shandong Pronvince Zibo City Official Hospital — Zibo, China (RECRUITING)
- Shandong Province Linzi District Hospital — Zibo, China (RECRUITING)
- Sichuan Province Zigong City No. 1 Hospital — Zigong, China (RECRUITING)
- Guizhou Province Zunyi Medical College Hospital — Zunyi, China (RECRUITING)
Study contacts
- Study coordinator: Chunxue Bai, M.D, Ph.D
- Email: bai.chunxue@zs-hospital.sh.cn
- Phone: +86 186-2117-0011
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Solitary Pulmonary Nodule, ResearchKit, CT screening, Early Diagnosis, Lung Cancer